GLP-1 receptor agonists: an updated review of head-to-head clinical studies
JM Trujillo, W Nuffer, BA Smith - Therapeutic advances in …, 2021 - journals.sagepub.com
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …
Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting
C Uzoigwe, Y Liang, S Whitmire, Y Paprocki - Diabetes Therapy, 2021 - Springer
Introduction The superior efficacy and safety of semaglutide once-weekly (QW), compared
with dulaglutide, liraglutide, or exenatide QW, have been demonstrated in the SUSTAIN …
with dulaglutide, liraglutide, or exenatide QW, have been demonstrated in the SUSTAIN …
Tirzepatide: A novel glucose-dependent Insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: The first Twincretin
AV Fanshier, BK Crews, MC Garrett… - Clinical …, 2023 - Am Diabetes Assoc
Tirzepatide is a dual-action glucose-dependent insulinotropic polypeptide/glucagon-like
peptide 1 (GLP-1) receptor agonist and the first drug in a new class known as twincretins. It …
peptide 1 (GLP-1) receptor agonist and the first drug in a new class known as twincretins. It …
[HTML][HTML] Greater adherence and persistence with injectable dulaglutide compared with injectable semaglutide at 1-Year follow-up: data from US clinical practice
R Mody, J Manjelievskaia, EH Marchlewicz… - Clinical Therapeutics, 2022 - Elsevier
Purpose Greater medication adherence and persistence have been associated with
improved glycemic control in patients with type 2 diabetes mellitus. This study compared …
improved glycemic control in patients with type 2 diabetes mellitus. This study compared …
Glucagon-like peptide 1 receptor agonists in type 2 diabetes mellitus: data from a real-world study in Spain
K Norrbacka, A Sicras-Mainar, J Lebrec, E Artime… - Diabetes Therapy, 2021 - Springer
Introduction This study aimed to describe utilization patterns, persistence, resource
utilization and costs in patients with type 2 diabetes mellitus initiating treatment with …
utilization and costs in patients with type 2 diabetes mellitus initiating treatment with …
Therapeutic delivery: industry update covering June 2020
I Simpson - Therapeutic Delivery, 2020 - Taylor & Francis
La Jolla Pharmaceuticals company to acquire Tetraphase Pharmaceuticals After a bidding
war that involved two other pharmaceutical companies, Tetraphase (MA, USA) announced …
war that involved two other pharmaceutical companies, Tetraphase (MA, USA) announced …